HUP0101689A2 - Anti-gp39-ellenanyagok alkalmazása lupusz és ezzel asszociált vesebetegség kezelésére és/vagy visszafejlesztésére - Google Patents
Anti-gp39-ellenanyagok alkalmazása lupusz és ezzel asszociált vesebetegség kezelésére és/vagy visszafejlesztéséreInfo
- Publication number
- HUP0101689A2 HUP0101689A2 HU0101689A HUP0101689A HUP0101689A2 HU P0101689 A2 HUP0101689 A2 HU P0101689A2 HU 0101689 A HU0101689 A HU 0101689A HU P0101689 A HUP0101689 A HU P0101689A HU P0101689 A2 HUP0101689 A2 HU P0101689A2
- Authority
- HU
- Hungary
- Prior art keywords
- receptor
- protein
- antibodies
- treatment
- cell
- Prior art date
Links
- 208000017169 kidney disease Diseases 0.000 title 1
- 206010025135 lupus erythematosus Diseases 0.000 title 1
- 101150013553 CD40 gene Proteins 0.000 abstract 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 4
- 108020003175 receptors Proteins 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 230000003844 B-cell-activation Effects 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
A találmány tárgyát a CD40-jelű B-sejt-antigén ellenreceptora képezi,amelyet az irodalomban alternatív módon CD40CR-nek, gp39-nek, vagylegújabban CD154-nek neveznek, valamint ezen receptor szolubilisligandumai, beleértve a CD40-fehérje legalább egy részét tartalmazófúziós molekulákat. Ez, legalábbis részben, azon a felismerésenalapul, hogy szolubilis CD40/immunoglobulin fúziós fehérje képes volthelper T-sejt-mediált B-sejt-aktiválódást gátolni úgy, hogy T-sejtmembránokon lévő, új, 39 kD méretű receptorfehérjéhez kötődött. Atalálmány tárgyát képezi közelebbről a lényegében tisztított CD40CR-receptor; továbbá a CD40CR szolubilis ligandumai, beleértve anti-gp39-ellenanyagokat és fragmenseiket, valamint a CD40-fehérje legalább egyrészét tartalmazó fúziós molekulák; és eljárások B-sejt-aktiválódásszabályzására, amelyek különösen hasznosak allergia vagy autoimmunbetegségek kezelésében. Más megközelítésből a találmány tárgyát anti-g39-ellenanyagok alkalmazása képezi, szisztémás lupusz eritematózus(SLE) vagy drog-indukált lupusz kezelésére. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5448898A | 1998-04-03 | 1998-04-03 | |
| PCT/US1999/007321 WO1999051258A1 (en) | 1998-04-03 | 1999-04-02 | USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101689A2 true HUP0101689A2 (hu) | 2001-08-28 |
| HUP0101689A3 HUP0101689A3 (en) | 2004-08-30 |
Family
ID=21991433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101689A HUP0101689A3 (en) | 1998-04-03 | 1999-04-02 | Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1067954A4 (hu) |
| JP (1) | JP2002510643A (hu) |
| KR (1) | KR20010072564A (hu) |
| CN (2) | CN1173735C (hu) |
| AU (1) | AU743824B2 (hu) |
| HU (1) | HUP0101689A3 (hu) |
| NO (1) | NO20004966L (hu) |
| TW (1) | TWI224969B (hu) |
| WO (1) | WO1999051258A1 (hu) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| PE20180802A1 (es) | 2015-08-05 | 2018-05-09 | Janssen Biotech Inc | Anticuerpos anti-cd154 y metodos de uso de estos |
| KR20200010294A (ko) | 2017-05-24 | 2020-01-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| CA2089229C (en) * | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| EE9900273A (et) * | 1997-01-10 | 2000-02-15 | Biogen, Incorporated | Luupusnefriidi ravi CD40L-vastaste ühenditega |
| AU5623398A (en) * | 1997-03-07 | 1998-09-22 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
| AU8266798A (en) * | 1997-06-27 | 1999-01-19 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
-
1999
- 1999-04-02 CN CNB998067563A patent/CN1173735C/zh not_active Expired - Fee Related
- 1999-04-02 WO PCT/US1999/007321 patent/WO1999051258A1/en not_active Application Discontinuation
- 1999-04-02 KR KR1020007011045A patent/KR20010072564A/ko active Search and Examination
- 1999-04-02 AU AU33796/99A patent/AU743824B2/en not_active Withdrawn - After Issue
- 1999-04-02 EP EP99915237A patent/EP1067954A4/en not_active Withdrawn
- 1999-04-02 HU HU0101689A patent/HUP0101689A3/hu unknown
- 1999-04-02 CN CNB200410078988XA patent/CN100352497C/zh not_active Expired - Fee Related
- 1999-04-02 JP JP2000542029A patent/JP2002510643A/ja not_active Withdrawn
- 1999-06-28 TW TW088105322A patent/TWI224969B/zh not_active IP Right Cessation
-
2000
- 2000-10-02 NO NO20004966A patent/NO20004966L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1173735C (zh) | 2004-11-03 |
| EP1067954A4 (en) | 2004-08-18 |
| HUP0101689A3 (en) | 2004-08-30 |
| AU743824B2 (en) | 2002-02-07 |
| EP1067954A1 (en) | 2001-01-17 |
| CN1303301A (zh) | 2001-07-11 |
| NO20004966L (no) | 2000-12-04 |
| JP2002510643A (ja) | 2002-04-09 |
| NO20004966D0 (no) | 2000-10-02 |
| CN100352497C (zh) | 2007-12-05 |
| AU3379699A (en) | 1999-10-25 |
| TWI224969B (en) | 2004-12-11 |
| CN1757413A (zh) | 2006-04-12 |
| KR20010072564A (ko) | 2001-07-31 |
| WO1999051258A1 (en) | 1999-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2279585T3 (es) | Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso. | |
| WO2002044426A3 (en) | Nod2 nucleic acids and proteins | |
| HUP0202532A2 (hu) | Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása | |
| WO2003068821A3 (en) | Anti-cd20 antibodies and fusion proteins thereof and methods of use | |
| EP1489099A3 (en) | Antibodies that bind the CD40CR receptor | |
| WO2000005249A3 (en) | Synthetic peptides and methods of use for autoimmune disease therapies | |
| FI963101A0 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut | |
| HK1112018A1 (en) | Human toll-like receptor proteins, related reagents and methods | |
| WO2001085790A3 (en) | Mammalian cytokine receptor subunit proteins, related reagents and methods | |
| WO2002020569A3 (en) | Mammalian genes; related reagents and methods | |
| PL374311A1 (en) | Methods for purifying protein | |
| WO2001090358A3 (en) | Mammalian receptor proteins; related reagents and methods | |
| ES2129622T3 (es) | Receptores para interleuquina-10 de mamifero. | |
| EP1433792A8 (en) | Human receptor proteins, related reagents and methods | |
| WO1995021922A3 (en) | Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use | |
| WO2003048194A3 (de) | Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie | |
| HUP0101689A2 (hu) | Anti-gp39-ellenanyagok alkalmazása lupusz és ezzel asszociált vesebetegség kezelésére és/vagy visszafejlesztésére | |
| CA2361987A1 (en) | Goodpasture antigen binding protein | |
| WO1996021020A3 (en) | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases | |
| MXPA02005236A (es) | Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. | |
| AU4721596A (en) | Anti dna antibody detection involving telomeric dna sequence recognition and binding | |
| DK1436320T3 (da) | T-celle-epitoper af cyn D 1-allergenet fra bermudagræspollen | |
| WO1997046683A3 (en) | Polynucleotides encoding secreted proteins | |
| WO1991015582A3 (en) | Purified rap gaps, rap gap sequences, and uses thereof | |
| BR9911609A (pt) | Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |